Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 6737 - 6744 of 12007 results
U.S. Mission in Russia to Temporarily Suspend NIV Issuance
August 22, 2017| Blog| Viewpoint
District Courts Remain Split on TC Heartland and Waiver of Improper Venue Defense
August 21, 2017| Blog| Viewpoint
DTSA and Ex Parte Seizure – Lessons from the First Ex Parte Seizure Under The DTSA
August 21, 2017| Blog| Viewpoint
Ten Foundation Questions for In-House Counsel About Form Arbitration Clauses
August 21, 2017| Blog| Viewpoint
CMS Proposes to Cancel Bundled Payment and Incentive Models
August 21, 2017| Blog| Viewpoint
The FTC’s Uber Consent Order: A Warning to Fast-Growing Companies
August 21, 2017| Alert| Viewpoint
Food Identity Disputes Continue to Impose High-Profile Pressure on FDA
August 20, 2017| Blog| Viewpoint
What In-House Counsel Need To Know About Their Form Arbitration Clauses – Ten Foundation Questions
August 19, 2017| Blog| Viewpoint
News & Press Releases
Mintz advised ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers, on a $75 million underwritten public offering of 2,482,692 shares of its common stock and pre-funded warrants to purchase up to 1,363,469 shares of its common stock. The common stock is listed on The Nasdaq Global Market under the symbol “AVBP.“
Mintz represented S2G Investments, a multi-stage investment firm focused on venture and growth-stage businesses across food & agriculture, oceans and energy, in its $40 million Series B financing of Sojo Industries, an industrial automation company that utilizes robotics, mobility, and software to deliver packaging and assembly solutions to the food and beverage industry.
Mintz advised Syntis Bio, a clinical-stage biopharmaceutical company revolutionizing oral therapies for obesity, diabetes, and rare diseases, on a $33 million oversubscribed Series A financing.
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts
Mintz On Air: Practical Policies – An Abridged Guide to Crisis Management
July 1, 2025| Podcast|
Health Law Diagnosed: PBM Update Spring 2025
June 10, 2025| Podcast|